Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Kenvue Inc. (KVUE) — XLP Consumer Staples · S&P 500 Profile |肯悅介紹

consumer-staplesS&P500xlpxlp-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Kenvue Inc. (KVUE) — Business, History & S&P 500 Profile |肯悅介紹

Kenvue company profile · consumer health (Tylenol, Band-Aid, Neutrogena, Listerine, Aveeno) · history · financial snapshot · S&P 500 rank #284 · 肯悅公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 30, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 28, 2025)
MARKET CAP
$37.11B
Oct 30, 2026 · Slickcharts (frozen benchmark)
S&P 500 WEIGHT
0.05%
Rank #284 · Oct 30, 2026 (Slickcharts)
FY2025 REVENUE
$15.12B
net sales (−2.1% YoY)
FY2025 NET INCOME
$1.47B
FY2025 net income

SNAPSHOT

TickerKVUE (NYSE)
CompanyKenvue Inc.
GICS sector / industryConsumer Staples (XLP) / Personal Care Products
S&P 500 rank (by weight)#284 · 0.05% (Oct 30, 2026)
Sector rank (by market cap)#17 in Consumer Staples (Oct 30, 2026)
Share price (frozen benchmark)$19.31 (Oct 30, 2026)
HeadquartersSummit, New Jersey
Founded2023 (spun off from Johnson & Johnson)
CEOKirk Perry (CEO, per the Feb 17, 2026 results release)
Employeesabout 22,000 (2026 profile)
Market cap$37.11B (Oct 30, 2026)

WHAT IT DOES

Kenvue is the consumer health company spun off from Johnson & Johnson in 2023, owning brands including Tylenol, Band-Aid, Neutrogena, Listerine, Aveeno, Johnson's Baby and Nicorette, sold in pharmacies, supermarkets and online in more than 165 countries. It is the world's largest pure-play consumer health company by revenue.

The model is brand plus shelf: trusted names command premium prices and prime retail placement, and the portfolio spans self care, skin health and essential health. FY2025 net sales were $15.124B, down 2.1% from $15.455B (organic −2.2%), operating income was $2.414B, net income was $1.470B, diluted EPS was $0.76 and adjusted diluted EPS was $1.08.

Two overhangs define the story: talc litigation inherited from Johnson & Johnson, and a pending Kimberly-Clark transaction — the company stated it would not provide forward-looking guidance due to the pending transaction.

BUSINESS SEGMENTS — FY2025

SegmentRevenueShareYoY
Self Care$6,378M—-2.3%
Skin Health and Beauty$4,114M—-3.0%
Essential Health$4,632M—-1.2%
Source: Kenvue FY2025 results release (Feb 17, 2026), Total Segment Net Sales table (fiscal year ended Dec 28, 2025). Total net sales $15,124M. Shares are not stated in the filed lines used and are shown as —.

HISTORY

YearMilestone
2023Spun off from Johnson & Johnson; initial public offering on the New York Stock Exchange
2023Shares begin trading as Kenvue, the world's largest pure-play consumer health company
2024Portfolio reshaping: divestitures and brand investments under a new strategy
2025FY2025 net sales reach $15.124B, with net income of $1.470B; Kimberly-Clark transaction pending

COMPETITIVE POSITION

  • Brand trust — Tylenol and Band-Aid carry decades of consumer trust.
  • Shelf placement — scale secures prime pharmacy and supermarket space.
  • Global reach — sales in more than 165 countries diversify demand.
  • Competition — Haleon, Procter & Gamble and private labels contest the same shelves.
  • Spin-off focus — independence lets management invest only in consumer health.

FINANCIAL SNAPSHOT — FY2025

Net sales$15.124B (−2.1% YoY; organic −2.2%)
Operating income$2.414B
Net income$1.470B
Diluted EPS / Adjusted diluted EPS$0.76 / $1.08
Source: Kenvue FY2025 results (fiscal year ended Dec 28, 2025), 10-K filed Feb 20, 2026. GAAP and adjusted EPS are stated separately, not mixed. Employee figure is a 2026 profile figure.

KEY RISKS

  • Talc litigation — inherited liabilities can still produce charges.
  • Pending transaction — the Kimberly-Clark deal may change strategy or ownership.
  • Private labels — retailer brands undercut branded prices.
  • Consumer softness — shoppers trade down in self care.
  • Currency — sales in more than 165 countries face translation effects.

WHY IT MATTERS FOR THE S&P 500

Kenvue is the S&P 500's consumer health name: at a 0.05% index weight and #17 in Consumer Staples by market cap, it is the index's main exposure to over-the-counter health and personal care.

Its brand volumes and organic growth are a standing read on the health consumer — self-care spending moves before broader staples data does.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 30, 2026 close) and Slickcharts S&P 500 analysis page (market cap)
FinancialsKenvue FY2025 results (fiscal year ended Dec 28, 2025), 10-K filed Feb 20, 2026, company profile sources
Sector classificationGICS (Personal Care Products) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

KVUE

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼KVUE(NYSE)
公司Kenvue Inc.
GICS 板塊/行業必需消費品(XLP)/個人護理產品
標普500排名(按權重)#284 · 0.05%(2026 年 10 月 30 日)
板塊內排名(按市值)必需消費品第 #17(2026 年 10 月 30 日)
股價(凍結基準)$19.31(2026 年 10 月 30 日)
總部美國新澤西州薩米特
成立2023 年(自強生分拆)
行政總裁Kirk Perry(行政總裁,按 2026 年 2 月 17 日業績公告)
員工約 22,000(2026 年簡介)
市值$37.11B(2026 年 10 月 30 日)

業務概覽

肯悅是 2023 年自強生分拆的消費保健公司,品牌包括 Tylenol、Band-Aid、Neutrogena、Listerine、Aveeno、強生嬰兒與 Nicorette,在 165 多個國家於藥房、超市與線上銷售;按收入為全球最大的純消費保健公司。

其模式為品牌加貨架:受信賴的品牌享有溢價與黃金零售位置,組合涵蓋自我護理、皮膚健康與基本健康。FY2025 淨銷售額為 $15.124B,同比下跌 2.1%(FY2024 為 $15.455B;有機 −2.2%),營業利潤為 $2.414B,淨利潤為 $1.470B,攤薄每股收益為 $0.76,經調整攤薄每股收益為 $1.08。

兩個陰影定義故事:自強生繼承的滑石粉訴訟,以及待定的金佰利交易——公司表示因交易待定而不提供前瞻指引。

業務板塊 — FY2025

板塊收入佔比同比
自我護理$6,378M—-2.3%
皮膚健康與美容$4,114M—-3.0%
基本健康$4,632M—-1.2%
來源:肯悅 FY2025 業績公告(2026 年 2 月 17 日)分部淨銷售額表(財政年度截至 2025 年 12 月 28 日)。淨銷售額合計 $15,124M。佔比未見於所用申報行,記為 —。

歷史沿革

年份里程碑
2023自強生分拆;在紐約證券交易所首次公開招股
2023以肯悅名義開始交易,為全球最大的純消費保健公司
2024組合重塑:新戰略下的資產出售與品牌投資
2025FY2025 淨銷售額達 $15.124B,淨利潤為 $1.470B;金佰利交易待定

競爭地位

  • 品牌信任——Tylenol 與 Band-Aid 承載數十年的消費者信任。
  • 貨架位置——規模確保黃金藥房與超市位置。
  • 全球覆蓋——165 多個國家的銷售分散需求。
  • 競爭——Haleon、寶潔與自有品牌爭奪同一批貨架。
  • 分拆聚焦——獨立令管理層只投資消費保健。

財務快照 — FY2025

淨銷售額$15.124B(同比 −2.1%;有機 −2.2%)
營業利潤$2.414B
淨利潤$1.470B
攤薄每股收益/經調整攤薄每股收益$0.76/$1.08
來源:肯悅 FY2025 業績(財政年度截至 2025 年 12 月 28 日)、2026 年 2 月 20 日提交的 10-K。GAAP 與經調整每股收益分開列示,不相混淆。員工數字為 2026 年簡介數字。

主要風險

  • 滑石粉訴訟——繼承的責任仍可產生費用。
  • 待定交易——金佰利交易可改變戰略或所有權。
  • 自有品牌——零售商品牌壓低品牌價格。
  • 消費疲軟——消費者在自我護理上降級。
  • 貨幣——165 多個國家的銷售面臨折算影響。

對標普500的重要性

肯悅是標普500的消費保健標的:指數權重 0.05%、必需消費品板塊市值第 #17,是指數對非處方保健與個人護理的主要敞口。

其品牌銷量與有機增長,是保健消費者的常設讀數——自我護理開支往往先於更廣泛的必需品數據變動。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 30 日收盤)及 Slickcharts 標普500分析頁(市值)
財務肯悅 FY2025 業績(財政年度截至 2025 年 12 月 28 日)、2026 年 2 月 20 日提交的 10-K、公司簡介來源
板塊分類GICS(個人護理產品),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

KVUE

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · KVUE
Data as of Oct 30, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Archer-Daniels-Midland Company (ADM) — XLP Consumer Staples · S&P 500 Profile |阿徹丹尼爾斯介紹Next · CBRE Group, Inc. (CBRE) — XLRE Real Estate · S&P 500 Profile |世邦魏理仕介紹

Entered 2026-11-01 20:35 · updated 2026-11-15 03:31 · rev 7